Biotech Values

[DewDiligence]

NEJM abstract_on Zepbound-vs-Wegovy study funded by LLY:

https://www.nejm.org/doi/full/10.1056/NEJMoa2416394

A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001). The least-squares mean change in waist circumference was -18.4 cm (95% CI, -19.6 to -17.2) with tirzepatide and -13.0 cm (95% CI, -14.3 to -11.7) with semaglutide (P<0.001).

These results are broadly consistent with prior data that did not come from a head-to-head trial.